Suggested remit - To appraise the clinical and cost effectiveness of rituximab within its marketing authorisation for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
This appraisal has now been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process STA Standard
ID number 1320

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 January 2024 Discontinued. This appraisal has now been discontinued.
20 March 2018 - 19 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual